Daxor receives FDA 510(k) clearance for next-gen blood volume analyzer

DAXOR CORP

FDA 510(k) clearance (K251087) for patent-pending rapid, hand-held BVA device.
Device provides results 3x faster, weighs 7 lbs, delivers lab-grade precision.
Clinical data: BVA-guided care reduced heart failure mortality by 86% (p<0.001), ICU mortality by 66%.
Over 75,000 tests shipped; developed under U.S. Army/DHA contract.
Management expects high demand driven by speed, simplicity, precision.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.